TNAs are selectively expressed in cancer cells, minimizing immune tolerance as well as autoimmune reactions (44); additionally, TNAs are more likely to engage CD8+ T-cell response and in this sense, the cancer immunotherapy could exploit personalized treatments, taking into account cancer patients ́ mutanome for a rational design of cancer therapeutic vaccine (45–47). The gene discussed is CD8A; the disease is cancer.